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To the Editors:  
The prodrug oxcarbazepine is an antiepileptic agent structurally resembling carbamazepine 
but differing in its metabolism. Oxcarbazepine inhibits voltage-dependent sodium channels 
resulting in an interruption of the epileptical discharge [1]. Oxcarbazepine is extensively 
metabolized by the liver into the active metabolite 10-monohydroxy-carbamazepine (MHD) 
via cytosolic keto-reductase enzymes. It is further deactivated by uridine diphosphate 
glucuronosyltransferase (UGT) to the metabolite 10,11-dihydroxy-derivative (DHD) [2]. 
Oxcarbazepine and MHD inhibit cytochrome P 450 (CYP) 2C19 and induce CYP3A4 and 
CYP3A5 but lack the ability for autoinduction [3]. 
Strong enzyme-inducers such as carbamazepine, phenytoin or phenobarbital are known to 
decrease the serum concentration of MHD by 13% -40% [4-7]. 
Rifampicin is another potent inducer of CYP isoenzymes, P-glycoprotein and UGT [8]. 
However, potential effects of rifampicin on the pharmacokinetics of oxcarbazepine are 
unknown. 
Here, we present a 33-year-old female (BMI 27.5 kg/m2, active smoker) on long-term 
oxcarbazepine treatment at a daily dose of 1.200 mg for epilepsy. Due to therapy-resistant 
acne vulgaris rifampicin 600 mg daily and clindamycin 300 mg b.i.d. were initiated. 
Therapeutic drug monitoring (TDM) of oxcarbazepine and MHD trough concentrations was 
conducted before, during and after the course of antibiotic therapy on day 0, 3, 7, 14, 21, 35, 
59, 83 und 92 days (figure 1). Coadministration with rifampicin resulted in a significant 
decrease of MHD serum concentrations by 49% on day 7, while oxcarbazepine 
concentrations remained stable. Oxcarbazepine dosing was adapted to maintain MHD 
concentrations within the therapeutic range. A 75% increase of the initial oxcarbazepine 
dose (final daily dose 2.100 mg) was required to achieve similar MHD target concentrations 
during rifampicin treatment compared to baseline. No other concomitant drugs were 
administered during this 10 weeks treatment. Neither the patient’s smoking habit nor the 
patient’s weight changed. After discontinuation of rifampicin, MHD serum concentrations 
increased despite an initial oxcarbazepine dose reduction. Finally the oxcarbazepine dose 
could be reduced to baseline dosage of 1.200 mg resulting in similar MHD concentrations 
before rifampicin treatment. The patient did not experience any epileptic seizure and 
adverse reaction during and after the period of coadministered rifampicin. 
 
In conclusion, this is the first report on coadministration of rifampicin and oxcarbazepine 
leading to reduced MHD serum concentrations. Since rifampicin is known to induce UGT, this 
could partially explain the reduced oxcarbazepine exposure. However, only 4% of MHD is 
supposed to be degraded by UGT in the absence of an UGT inducer. MHD concentrations 
decreased by 49%, while a dose increase of 75% was necessary for oxcarbazepine during 
rifampicin therapy. Serum levels between 10-35 mg/L have been suggested for the 
prevention of epileptic seizures [9]. Although the clinical significance of this drug-drug 
interaction is not exactly known, decreased MHD concentrations may result in a potential 
reduction of oxcarbazepine efficacy leading to seizures. If oxcarbazepine and rifampicin are 
administered concurrently, close monitoring of clinical response to oxcarbazepine and TDM 
of the active metabolite MHD should be performed. Dose adaptions of oxcarbazepine might 
be necessary after initiation and discontinuation of the potent CYP inducer rifampicin. 
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 Figure 1: Time course of oxcarbazepine and MHD trough level and oxcarbazepine dose adaptions related to initiation of rifampicin. Therapeutic range (10-35 
mg/L) implicates for oxcarbazepine plus MHD [9]; Oxc oxcarbazepine, MHD monohydroxy-derivative  
